Want to see IDTA full AI Analyst Report?
Top Page
Identa
(OTC:IDTA)
Select Model
Select Model
Rating:69Neutral
Price Target:
$0.30
▲(34.55% Upside)
Action:Reiterated
Date:08/20/26
The score is driven mainly by improving financial performance (stronger TTM profitability and better leverage) but held back by historical volatility and inconsistent cash flow. Valuation is a clear positive due to the low P/E, while technicals are supportive yet tempered by overbought RSI.
Positive Factors
Improved Profitability
The recent combination of revenue growth and healthy gross, operating, and net margins indicates improved earnings power. If maintained, stronger profitability can support reinvestment and resilience, although the company’s historical volatility warrants caution.
Negative Factors
Uneven Revenue Performance
Revenue declines in multiple recent years indicate inconsistent demand or execution, making the latest rebound harder to extrapolate. Uneven sales performance can limit operating leverage and reduce confidence that current profitability will persist through the cycle.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability
The recent combination of revenue growth and healthy gross, operating, and net margins indicates improved earnings power. If maintained, stronger profitability can support reinvestment and resilience, although the company’s historical volatility warrants caution.
Read all positive factors
Identa (IDTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21M
Dividend YieldN/A
Average Volume (3M)1.19K
Price to Earnings (P/E)8.4
Beta (1Y)-1.17
Revenue Growth57.25%
EPS GrowthN/A
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)0.04
Shares Outstanding4,045,589
10 Day Avg. Volume1,429
30 Day Avg. Volume1,191
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.81
Price to Sales (P/S)0.53
P/FCF Ratio17.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Identa Business Overview & Revenue Model
Company Description
IDenta Corp. operates as a detection and forensic science company. The company offers drug testing kits, explosives testing kits, aero chamber sniffer, forensic, urine drug testing, and saliva drug testing products. It provides its solutions to la...
How the Company Makes Money
null...
Identa Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86M | 1.34M | 1.46M | 1.05M | 1.34M | 1.39M |
| Gross Profit | 958.46K | 686.57K | 756.46K | 662.98K | 983.39K | 1.02M |
| EBITDA | 254.66K | 128.96K | 328.40K | 57.13K | 199.56K | 135.57K |
| Net Income | 141.05K | 99.04K | 258.34K | 14.64K | 162.71K | 69.18K |
Balance Sheet | ||||||
| Total Assets | 2.38M | 1.92M | 1.66M | 1.53M | 1.56M | 1.23M |
| Cash, Cash Equivalents and Short-Term Investments | 669.76K | 379.42K | 735.95K | 264.29K | 368.90K | 347.15K |
| Total Debt | 661.18K | 645.20K | 640.23K | 785.37K | 820.28K | 511.63K |
| Total Liabilities | 1.08M | 1.04M | 921.01K | 1.01M | 1.10M | 799.32K |
| Stockholders Equity | 1.30M | 879.16K | 742.31K | 516.12K | 459.63K | 430.01K |
Cash Flow | ||||||
| Free Cash Flow | 253.53K | 40.28K | 555.85K | -151.97K | 61.56K | -221.97K |
| Operating Cash Flow | 284.25K | 56.94K | 561.89K | -137.63K | 94.31K | -88.95K |
| Investing Cash Flow | -87.01K | -48.05K | -260.40K | -8.15K | -8.61K | -133.02K |
| Financing Cash Flow | 276.22K | -43.78K | -151.47K | -23.53K | -63.95K | 28.02K |
Identa Technical Analysis
Positive
0.22
Price Trends
0.23
Positive
0.20
Positive
0.21
Positive
Market Momentum
0.02
Negative
83.33
Negative
56.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDTA, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.23, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 83.33 is Negative, neither overbought nor oversold. The STOCH value of 56.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDTA.
Identa Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.21M | 8.43 | 4.97% | ― | 57.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.60M | -0.27 | -174.16% | ― | 38.09% | 54.22% | |
44 Neutral | $6.73M | -0.71 | -513.22% | ― | ― | 98.17% | |
43 Neutral | $3.24M | -0.05 | -358.76% | ― | -23.17% | 67.18% | |
41 Neutral | $886.20K | >-0.01 | -337.10% | ― | -27.39% | 99.29% |
* Healthcare Sector Average
IDTA
Identa
0.30
0.09
45.63%
BNBX
BNB Plus
0.14
-3.32
-95.87%
NDRA
ENDRA Life Sciences
4.49
0.04
0.90%
INBS
Intelligent Bio Solutions
2.51
-12.19
-82.93%
BIAF
bioAffinity Technologies, Inc.
0.40
-7.08
-94.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.